Trial Profile
64Cu-DOTA-nivolumab PET imaging in patients with malignant melanoma or non-small cell lung cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer
- Focus Diagnostic use
- 27 Mar 2017 New trial record